Rasio utang jangka dawa marang modal proqr.com (PRQR)

ProQR Therapeutics N.V. (PRQR) scientific management is implementing advanced RNA editing methods, prioritizing the most promising developments. Production capacities are concentrated in the Netherlands, while scaling output is outsourced to CDMO partners to optimize costs. However, a revenue shortfall and R&D expenses create a financial deficit, where the indicator stands at 0.11. This price chart illustrates the dynamics of the company's long-term debt-to-equity ratio.

This indicator assesses financial stability by comparing the volume of liabilities with maturities exceeding one year against total equity to determine the level of credit risk. An analysis of the long-term debt-to-equity ratio confirms that ProQR Therapeutics N.V. (PRQR) carries no borrowed capital, as the development of its R&D platforms is fully funded through strategic alliances with pharma behemoths without resorting to external loans.